OKYO Pharma Ltd (NASDAQ:OKYO) said its chief development officer and director Gary Jacob has purchased about 31,000 shares of the company at $1.59 each.
The transaction increases his total holdings to about 109,000.
The clinical-stage company is developing treatments for neuropathic corneal pain and inflammatory eye diseases.